iCAD, CancerIQ announce partnership to integrate AI-enabled technology

iCAD and CancerIQ announced a new partnership to create a best-in-class breast health care solution. The partnership will provide a seamless way to uniquely inform physicians and patients of cancer risk, identify breast cancer at earlier stages, when treatments work best, and increase patient adherence to their personalized care plans. Together, these solutions will combine elements from iCAD‘s artificial intelligence-enabled ProFound Breast Health Suite with CancerIQ’s software and services, giving users a 2.4x more accurate prediction of breast cancer risk by combining AI-informed 1- or 2-year risk with lifetime risk, as well as a unique care management and patient activation workflow solution proven to more than double adherence to payer-supported supplemental screening recommendations. “This partnership will streamline how patients and physicians use our collective health data to schedule preventative screenings and manage breast health care in a way that will save lives,” said Dana Brown, president and CEO of iCAD. “We look forward to a long-term relationship with CancerIQ that will create meaningful, actionable information in terms of proactive and personalized care benefiting both medical providers and the patients they serve.” The partnership aims to combine CancerIQ’s lifetime risk score and genetic risk data with iCAD’s ProFound Density assessment score and ProFound Risk, the only AI-informed short-term cancer risk assessment that offers the industry’s highest AUC for providing a one-year future risk estimation based on a 2D or 3D screening mammogram.